StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.31−0.45 (-3.27%)

Close on Nov 18, 2026Market cap $882.44MP/E –Yield 0.00%

Latigo Biotherapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$17.50M–
Q2 FY2026Jun 30, 2026$21.23M–
Q3 FY2025Sep 30, 2025$22.10M–
Q2 FY2025Jun 30, 2025$22.92M–

More Latigo Biotherapeutics figures

See a number that looks wrong?